Healthcare Sector

VRTX

Market Tracker

  • VRTX (Selected)

    Vertex Pharmaceuticals Incorporated

VRTX Most Active Options Strike Prices Whale BUY Activity - 5 day

Loading Data..

Represents the strikes that had the highest premium of whale flow (on the ASK side) over the past 5 trading days.

VRTX Most Active Options Strike Prices Whale SALES Activity - 5 day

Loading Data..

Represents the strikes that had the highest premium of whale flow (on the BID side) over the past 5 trading days.

VRTX Open Interest Trend

Loading Data..

Total Open Interest of Calls & Puts across all strikes and expirations over the past 16 trading days.

VRTX Largest 1-Day Open Interest Movements

Expires Type Strike OI Change Percent
07/17/2026 CALL $490.00 404 +96 +31.17%
07/17/2026 PUT $440.00 386 +91 +30.85%
09/18/2026 CALL $540.00 69 +49 +245.00%
06/18/2026 CALL $465.00 78 +47 +151.61%
07/17/2026 CALL $500.00 179 +40 +28.78%
07/24/2026 CALL $460.00 36 +36
06/18/2026 PUT $440.00 198 -15 -7.04%
06/18/2026 PUT $450.00 589 -15 -2.48%
07/24/2026 PUT $350.00 56 -15 -21.13%
06/18/2026 CALL $460.00 484 -34 -6.56%
07/31/2026 PUT $350.00 55 -35 -38.89%
06/18/2026 CALL $450.00 571 -37 -6.09%

Contracts with largest changes in open interest from the previous trading day to the current/most recent.

VRTX Major Holders

Name Pct Held Shares Total
Vanguard Total Stock Market Index Fund 2.94% 7.53M 2.18B
Vanguard 500 Index Fund 2.21% 5.66M 1.64B
Vanguard Specialized-Health Care Fund 1.82% 4.66M 1.35B
Growth Fund Of America Inc 1.74% 4.46M 1.29B
Invesco ETF Tr-Invesco QQQ Tr, Series 1 ETF 1.45% 3.72M 1.08B
Invesco ETF Tr-Invesco NASDAQ 100 ETF 1.44% 3.69M 1.07B
New Perspective Fund Inc 1.15% 2.94M 852.45M
Fidelity Contrafund Inc 1.10% 2.83M 820.18M
SPDR S&P 500 ETF Trust 1.07% 2.74M 794.52M
Fidelity 500 Index Fund 1.06% 2.71M 786.56M
iShares Core S&P 500 ETF 0.88% 2.27M 657.44M
AB Large Cap Growth Fund 0.81% 2.08M 603.8M
Vanguard Institutional Index Fund-Institutional Index Fund 0.74% 1.89M 548.97M
American Balanced Fund 0.73% 1.86M 539.44M
MFS Series Trust II-MFS Growth Fund 0.67% 1.71M 496.09M
Loomis Sayles Growth Fund 0.61% 1.57M 455.67M
Legg Mason Clearbridge Aggressive Growth Fd 0.54% 1.39M 404.07M

VRTX News

  • Vertex Says Pediatric CASGEVY Data Show Consistent Benefits In Rare Blood Disorders

    06/11 12:20 pm

    Benzinga

    Read more
  • Kyverna Therapeutics vs. Vertex Pharmaceuticals: Which Drug Developer Stock Is a Better Buy in 2026?

    06/08 02:34 pm

    The Motley Fool

    Read more
  • CRISPR Therapeutics Stock Is Absurdly Cheap -- Here's Why Analysts See 437% Upside Potential

    06/03 12:30 pm

    The Motley Fool

    Read more
  • CRISPR Therapeutics vs. Editas Medicine: Which Gene Editing Stock Is a Better Buy in 2026?

    05/31 12:11 pm

    The Motley Fool

    Read more
  • Better Gene-Editing Stock: CRISPR Therapeutics or Beam Therapeutics?

    05/25 08:35 pm

    The Motley Fool

    Read more
  • 1 Top Wall Street Analyst Thinks CRISPR Therapeutics Could More Than Double. Should You Buy the Stock Hand Over Fist?

    05/11 04:15 pm

    The Motley Fool

    Read more
  • Global Personalized Medicine to Transform Modern Healthcare and Cross USD 1 Trillion by 2034 | DelveInsight

    05/11 01:00 pm

    GlobeNewswire Inc.

    Read more
  • Is This Millionaire-Maker Biotech Stock a Buy Right Now?

    05/06 03:30 am

    The Motley Fool

    Read more
  • Got $1,000? Which of These Beaten-Down Healthcare Stocks Is Worth Buying?

    05/02 03:30 am

    The Motley Fool

    Read more
  • Want to Build Real Wealth in Healthcare? These Stocks Are Worth Considering

    04/30 06:10 am

    The Motley Fool

    Read more
  • What's the Next Big Thing After GLP-1 Drugs? CRISPR Therapeutics May Have the Answer.

    04/30 05:10 am

    The Motley Fool

    Read more
  • Should You Forget This High-Yield Pharma Stock and Buy a Growth Name Instead?

    04/30 03:10 am

    The Motley Fool

    Read more
  • IgA Nephropathy Market Forecast to 2036: Novel Therapies and Key Growth Drivers Fuel Expansion | DelveInsight

    04/29 01:00 pm

    GlobeNewswire Inc.

    Read more
  • 3 Healthcare Stocks With the Most Durable Competitive Moats

    04/23 04:05 am

    The Motley Fool

    Read more
  • CRISPR Therapeutics Has Major Catalysts Ahead. Is This Biotech Stock a Screaming Buy?

    04/21 01:30 pm

    The Motley Fool

    Read more
  • Is Vertex Pharmaceuticals' Empire in Trouble?

    04/16 03:26 pm

    The Motley Fool

    Read more
  • Biotechs Racing to Translate Longevity Science Into Real Therapies -- And One Microcap Company Is Producing An Anti-Aging Protein From Genetically Modified, Encapsulated Cells

    04/10 09:55 am

    Benzinga

    Read more
  • Global DNA Read, Write and Edit Market to Surge to $67.7 Billion by 2030, Driven by CRISPR Advances, Genomic Diagnostics and Expanding Clinical Applications

    04/07 01:44 pm

    GlobeNewswire Inc.

    Read more
  • Idiopathic Membranous Nephropathy Market is Predicted to Reach USD 1 Billion by 2036 Due to Rising Therapeutic Options | DelveInsight

    04/06 01:00 pm

    GlobeNewswire Inc.

    Read more
  • Where Will Vertex Pharmaceuticals Be in 1 Year?

    03/25 04:02 pm

    The Motley Fool

    Read more
  • Anti-Aging Protein Research Takes a Step Forward with Cell Cloning

    03/24 11:05 am

    Benzinga

    Read more
  • CRISPR Therapeutics Stock: Is It a Bargain Buy Right Now?

    03/23 01:30 pm

    The Motley Fool

    Read more
  • My Top 3 Drug Stocks for March 2026

    03/20 06:30 am

    The Motley Fool

    Read more
  • Best Growth Stock to Buy Right Now: Eli Lilly vs. Vertex Pharmaceuticals

    03/19 02:30 pm

    The Motley Fool

    Read more
  • UNCF NEW ENGLAND Raises Record-Breaking $800,000 for HBCUs and Student Success

    03/19 07:00 am

    GlobeNewswire Inc.

    Read more
  • Is Vertex Pharmaceuticals Heading to $600?

    03/15 09:15 pm

    The Motley Fool

    Read more
  • Oil Crashes 10%, Stocks Rebound On Trump End-Of-War Signals: What's Moving Markets Tuesday?

    03/10 01:03 pm

    Benzinga

    Read more
  • Vertex's New Kidney Drug Delivers Big Trial Win, Stock Jumps

    03/10 09:24 am

    Benzinga

    Read more
  • 2 Biotech Giants to Buy in 2026

    03/05 09:15 am

    The Motley Fool

    Read more
  • Forget CRISPR Therapeutics: This Gene‑Editing Player Already Boasts the Profits It Dreams Of

    03/04 02:23 pm

    The Motley Fool

    Read more
  • Absci Strengthens Clinical Leadership with Appointment of Ransi Somaratne, M.D., FACC, MBA as Chief Medical Officer

    03/03 09:00 am

    GlobeNewswire Inc.

    Read more
  • 2 Top Healthcare Stocks to Buy in February

    02/26 03:15 pm

    The Motley Fool

    Read more
  • Forget Centessa Pharmaceuticals: This Rare‑Disease Specialist Has a Superior Portfolio and Pipeline

    02/26 02:30 pm

    The Motley Fool

    Read more
  • The Ultimate Biotech Stock to Buy With $500 Right Now

    02/24 04:30 am

    The Motley Fool

    Read more
  • Could Vertex Stock Help Turn $100,000 Into $1 Million by 2036?

    02/22 07:30 pm

    The Motley Fool

    Read more
  • CRISPR Therapeutics Gains After Earnings as Pipeline Hope Grows

    02/20 11:22 am

    Investing.com

    Read more
  • The Blastoff-Ready Biotech Stock You'll Kick Yourself for Not Buying in 2026

    02/13 04:10 pm

    The Motley Fool

    Read more
  • Small Caps, Silver Rally As Inflation Cools Further: What's Moving Markets Friday?

    02/13 02:48 pm

    Benzinga

    Read more
  • CRISPR Therapeutics Spotlights Momentum For Lead Gene Therapy As Adoption Widens

    02/13 02:45 pm

    Benzinga

    Read more
  • 1 Reason I'd Buy Vertex Pharmaceuticals Stock and Never Sell

    02/10 02:15 pm

    The Motley Fool

    Read more
  • Should You Buy Vertex Before Feb. 12?

    02/10 10:35 am

    The Motley Fool

    Read more
  • Targeted Cancer Therapy Market to Reach US$ 175.48 Billion by 2035 Driven by Precision Oncology Adoption, ADC Innovation, and Regulatory Productivity Says Astute Analytica

    02/03 02:56 am

    GlobeNewswire Inc.

    Read more
  • Autologous Cell Therapy Market Size to Reach US$ 44.55 Billion by 2033 | Astute Analytica

    01/27 02:43 pm

    GlobeNewswire Inc.

    Read more
  • Breaking Barriers: How 2026’s Top Clinical Leaders Are Disrupting Chronic Disease Markets

    01/23 01:56 pm

    GlobeNewswire Inc.

    Read more
  • Stock Market Today, Jan. 15: ImmunityBio Surges After Anktiva Revenue Jumps 700%

    01/15 06:27 pm

    The Motley Fool

    Read more
  • Prediction: These Could Be the Best-Performing Healthcare Stocks Through 2030

    01/14 12:15 pm

    The Motley Fool

    Read more
  • Prediction: 2 Healthcare Stocks That Will Be Worth More Than Pfizer by the End of 2026

    01/09 10:30 am

    The Motley Fool

    Read more
  • Entrada Therapeutics Highlights Progress Across its Portfolio of RNA-based Therapeutics for the Treatment of Neuromuscular and Ocular Diseases

    01/08 08:00 am

    GlobeNewswire Inc.

    Read more
  • My 10 Top Stocks to Buy to Start the New Year Off Right

    01/05 09:15 pm

    The Motley Fool

    Read more
  • Gene Therapy: 5 Biotech Stocks Chasing the $36B Prize

    01/02 02:29 pm

    Benzinga

    Read more
👀

Follow the Whales in real-time.

🎁

Take 50% OFF With Code: